Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by DavidKingCanadaon Jun 16, 2021 10:57am
168 Views
Post# 33395087

RE:RE:RE:RE:RE:RE:RE:RE:Game Plan

RE:RE:RE:RE:RE:RE:RE:RE:Game PlanI'm not really too sure what you want Gene and Elliot to do? With the Boston Group having already Invested "Millions" of Dollars and the Approval of Aducanumab I don't believe Gene or Elliot are steering the Ship anymore. Keep in mind I have only been Invested for 1 year now and don't know too much about their previous endeavours. 
I'm curious as to who they have in mind for a new CEO come Years End. Any speculations? This too will definitely Increase the SP when it is announced. As RC has stated in the past, PMN can be a volatile stock and you have to learn when to Buy the dip and Sell soon after a PR is released. This way you can accumulate more Shares and when PMN hits 1-2 Dollar mark I am buying all you guys Beer and Chips! I have a special bottle of Crown Royal for my friend M101 ;)
<< Previous
Bullboard Posts
Next >>